Comparison of Different Chronic Maintenance Antithrombotic Strategies in Patients with Coronary Artery Disease: A Systematic Review and Network Meta-Analysis

Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Association for Acute CardioVascular Care (ACVC), and European Association of Preventive Cardiology (EAPC)

(2023) Eliano Pio Navarese et al.   European Heart Journal-Cardiovascular Pharmacotherapy

Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study

(2022) Jeehoon Kang et al.   CIRCULATION

Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial

(2021) Bon-Kwon Koo et al.   LANCET

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

(2020) Jean-Philippe Collet et al.   EUROPEAN HEART JOURNAL

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes

(2019) Juhani Knuuti et al.   EUROPEAN HEART JOURNAL

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

(2019) Deepak L Bhatt et al.   LANCET

RoB 2: a revised tool for assessing risk of bias in randomised trials

(2019) Jonathan A C Sterne et al.   BMJ-British Medical Journal

Extended Duration of Dual‐Antiplatelet Therapy After Percutaneous Coronary Intervention: How Long Is Too Long?

(2019) Charles E. Howard et al.   Journal of the American Heart Association

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

(2018) Stuart J Connolly et al.   LANCET

2018 ESC/EACTS Guidelines on myocardial revascularization

(2018) Franz-Josef Neumann et al.   EUROPEAN HEART JOURNAL

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS

(2017) Marco Valgimigli et al.   EUROPEAN HEART JOURNAL

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

(2017) John W. Eikelboom et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials

(2015) Jacob A. Udell et al.   EUROPEAN HEART JOURNAL

Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial

(2015) Gérard Helft et al.   EUROPEAN HEART JOURNAL

Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction

(2015) Marc P. Bonaca et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial

(2014) Jean-Philippe Collet et al.   LANCET

Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents

(2014) Laura Mauri et al.   NEW ENGLAND JOURNAL OF MEDICINE

Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation

(2013) Cheol Whan Lee et al.   CIRCULATION

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

(2009)   LANCET